Traders sold shares of Becton, Dickinson and Company (NYSE:BDX) on strength during trading hours on Friday. $37.97 million flowed into the stock on the tick-up and $65.30 million flowed out of the stock on the tick-down, for a money net flow of $27.33 million out of the stock. Of all companies tracked, Becton, Dickinson and had the 25th highest net out-flow for the day. Becton, Dickinson and traded up $1.50 for the day and closed at $193.06

Several equities research analysts have weighed in on the company. Wells Fargo & Company assumed coverage on Becton, Dickinson and in a report on Friday. They issued an “outperform” rating and a $225.00 price objective for the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reiterated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus price target of $198.69.

The company has a market capitalization of $43.93 billion, a P/E ratio of 55.91 and a beta of 1.06. The firm’s 50-day moving average price is $199.01 and its 200-day moving average price is $191.58.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.35 earnings per share. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.51%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 75,904 shares of company stock valued at $15,242,688. 1.40% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the period. BlackRock Inc. lifted its holdings in Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after buying an additional 15,887,611 shares during the period. State Street Corp lifted its holdings in Becton, Dickinson and by 3.5% during the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after buying an additional 342,873 shares during the period. JPMorgan Chase & Co. lifted its holdings in Becton, Dickinson and by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock worth $727,863,000 after buying an additional 242,081 shares during the period. Finally, Northern Trust Corp lifted its holdings in Becton, Dickinson and by 4.0% during the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after buying an additional 106,966 shares during the period. Institutional investors own 87.12% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/09/22/investors-sell-becton-dickinson-and-company-bdx-on-strength-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.